Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Receivables (2016 - 2025)

Angiodynamics (ANGO) has disclosed Receivables for 15 consecutive years, with $44.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 2.96% year-over-year to $44.4 million, compared with a TTM value of $44.4 million through Nov 2025, up 2.96%, and an annual FY2025 reading of $42.9 million, down 1.65% over the prior year.
  • Receivables was $44.4 million for Q4 2025 at Angiodynamics, up from $42.6 million in the prior quarter.
  • Across five years, Receivables topped out at $53.6 million in Q3 2022 and bottomed at $33.2 million in Q1 2021.
  • Average Receivables over 5 years is $44.9 million, with a median of $43.5 million recorded in 2024.
  • The sharpest move saw Receivables skyrocketed 51.3% in 2022, then dropped 20.48% in 2024.
  • Year by year, Receivables stood at $38.2 million in 2021, then soared by 38.34% to $52.9 million in 2022, then fell by 2.36% to $51.6 million in 2023, then decreased by 16.37% to $43.2 million in 2024, then grew by 2.96% to $44.4 million in 2025.
  • Business Quant data shows Receivables for ANGO at $44.4 million in Q4 2025, $42.6 million in Q3 2025, and $42.9 million in Q2 2025.